SPRING GROUP MEETING
Seattle
Cancer Survivorship Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON
Cancer Control & Prevention Committees

Leadership
Vice-Chair NCORP: Dawn L. Hershman, MD, MS
Cancer Care Delivery Co-Chairs: Dawn L. Hershman, MD, MS
................................................. Scott D. Ramsey, MD, PhD
Cancer Survivorship Co-Chairs: ................................................................. Halle C.F. Moore, MD
................................................................. Melinda L. Irwin, PhD, MPH
Palliative & End of Life Co-Chairs: Robert S. Krouse, MD, FACS
................................................................. Marie Bakitas, DNSc, CRNP
Prevention and Epidemiology Co-Chairs: ................................................. Marlan L. Neuhausen, PhD, RD
Symptom Control & QOL Co-Chairs: ........................................................ Michael J. Fisch, MD, MPH
................................................................. Norah Lynn Henry, MD, PhD
Executive Officers: Katherine D. Crew, MD (CCD, Prevention, Symptom Control)
................................................................. Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
Senior Advisor: Frank L. Meykens, Jr., MD
Statisticians: Katherine Guthrie, PhD
................................................................. Cathy Tangen, DrPH
................................................................. Joseph M. Unger, PhD
................................................................. Kathryn B. Arnold, MS
................................................................. Amy K. Darke, MS
................................................................. Danika Lew, MA
................................................................. Sarah Colby, MS
Administrative Lead SDMC: Monica Yee, CCRP

Scientific Leadership
NCORP Representative: Scott Edward Delacroix, Jr, MD
................................................................. Helen Heng-Shan Moon, MD
Radiation Oncology: Eileen P. Connolly, MD, PhD (CCD, Prevention)
................................................................. Kiri A. Cook, MD (Survivorship, Symptom Control)
................................................................. Erin F. Gillespie, MD (Symptom Control)
Surgery Committee: ................................................................. Robert S. Krouse, MD, FACS
Translational Medicine: ................................................................. James Rae, PhD

Liaisons:
Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
Breast Committee: Mariya Rozenblit, MD (Survivorship)
................................................................. Helen K. Chew, MD (Symptom Control)
................................................................. Dawn Hershman, MD, MS (CCD)
................................................................. Banu Arun, MD (Prevention)
................................................................. Philip Lammers, MD
Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
................................................................. Jason M. Prosek, MD
Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
................................................................. Afsaneh Barzi, MD (CCD)
Genitourinary Committee: Clara Hwang, MD
................................................................. Sarah P. Psutka, MD
International Liaison: Kathy S. Albain, MD
Leukemia Committee: Stephanie B. Tsai, MD
Lung Committee: Gary E. Goodman, MD
Lymphoma Committee: Hayder Saeed, MD
Melanoma Committee: Sancy Leachman, MD, PhD
................................................................. Thach-Giao Truong, MD (Survivorship)
Recruitment & Retention: Allison M. Caban-Holt, PhD
Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
................................................................. Krishna Soujanya Gunturu, MD (Survivorship)
................................................................. Mina S. Sedrak, MD (CCD)
................................................................. Katherine D. Crew, MD (Symptom Control)
................................................................. Michael J. Fisch, MD (Symptom Control)
Veterans Affairs: Yeun-Hea Anna Park, MD (Symptom Control)
................................................................. Neha Patel, MD (Survivorship)
................................................................. Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates
Oncology Research Professionals:
CRA: Amy Jo Koffman, BS, CCRC
................................................................. Samantha Wright, MS, CRP
................................................................. Shirley S. Sui, BS
Nurses: Connie Szczepanek, RN, BSN
................................................................. Melyssa W. Foust, MSN, RN
Pharmaceutical Sciences Committee: Kimberley McConnell, PharmD
................................................................. Su (“Coco”) Yang, PharmD, PhD
SDMC Data Coordinators: Kimberly Carvalho, BA
................................................................. Sam Dzingale, BA
................................................................. Matthew Eng, PharmD
................................................................. Diane Liggett, BS, CCRP
................................................................. Roxanne Topacio, CCRP
Recruitment & Retention Specialist: Monica Yee, BA, CCRP
Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
................................................................. Amy Geschwender, PhD (Symptom Control)
................................................................. Hartley “Lee” M. Jones, MBA (Survivorship)
................................................................. Cheryl L. Jernigan, CPA (Prevention)
Sr. Protocol Project Manager (CCD and Prevention): Patricia O’Kane
Protocol Project Manager (Survivorship): Megan Keim
Protocol Project Manager (Symptom Control): Justine Trevino
Protocol Project Manager (Palliative Care): Andrea Garcia
Clinical Trials Program Manager (Palliative Care): Laura Gildner, MS
Clinical Trials Program Manager (CCD; Prevention; Survivorship; Symptom Control): Mariah Norman, MS
Cancer Survivorship Committee

Leadership
Co-Chairs: .......................................................... Melinda Irwin, PhD, MPH
.......................................................... Halle Moore, MD

Time/Location
Friday, April 5, 2024 7:15 a.m. - 9:15 a.m.
Room: Columbia D (Level 3)

Agenda
Welcome: Melinda Irwin and Halle Moore
Patient Advocate Update: Lee Jones

Updates:
Justin Floyd and Monika Leja: S1501, “Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer.”

Suzie Zick and Heather Greenlee: Testing the Fatigue Reduction Diet in People with Early Stage Breast Cancer: A Randomized Controlled Trial, The GUIDE Study

Rina Fox and Terry Badger: App-supported sleep coaching among cancer survivors and their bedroom partners

Pragmatic Trial Emerging Concept
Krishna Gunturu: S2013 I-CHECKIT: Immune CHECKpoint Inhibitor Toxicity analysis (QOL and Symptom Control Committee)

Group: Late and lasting effects for cancer survivors following immunotherapy.

Liaison Updates/Other Business

Active Study

Concepts in Development

XXXXX, “Randomized, phase II trial of vortioxetine for the reduction of ADT-induced cognitive impairment”. Dr. L. Graham. Pending drug procurement plan.

XXXXX, “Phase III Trial of an App-Supported Sleep Coaching Intervention in Post-Treatment Survivors of Diverse Cancers and their Bedroom Partners”. Drs. Rina Fox and Terry Badger. One-pager reviewed by DCP leadership on 1/26/24. Planned R01 submission for June deadline.

Closed Study

Publications
The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts


Submitted Manuscripts
None this cycle
## Cancer Survivorship Committee

*Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study*

<table>
<thead>
<tr>
<th>Institution/Network</th>
<th>A211901S1501</th>
<th>A211901</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascension Providence Hospitals - Southfield</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Baptist Mem Health Care/Mid South MU-NCORP</td>
<td>7</td>
<td>-</td>
</tr>
<tr>
<td>Bay Area Tumor Institute NCORP</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>CWRU Case Comprehensive Cancer Center LAPS</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td>Cancer Research for the Ozarks NCORP</td>
<td>11</td>
<td>-</td>
</tr>
<tr>
<td>City of Hope Comprehensive Cancer Center</td>
<td>49</td>
<td>-</td>
</tr>
<tr>
<td>Columbia University Minority Underserved NCORP</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>CommonSpirit Health Research Institute</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center LAPS</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Georgia NCI Community Oncology Research Program</td>
<td>13</td>
<td>-</td>
</tr>
<tr>
<td>Gulf South Minority Underserved NCORP</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Heartland Cancer Research NCORP</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Henry Ford Hospital</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Kaiser Permanente NCI Comm Oncology Research Program</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>King Faisal Specialist Hospital and Research Centre</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Lahey Hospital and Medical Center</td>
<td>6</td>
<td>-</td>
</tr>
<tr>
<td>Loyola University Medical Center</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Medical U of South Carolina Minority Underserved NCORP</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Michigan Cancer Research Consortium NCORP</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>23</td>
<td>-</td>
</tr>
<tr>
<td>Montana Cancer Consortium NCORP</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>NCORP of the Carolinas (Prisma Health NCORP)</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>National Cancer Center-Korea</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>New Mexico Minority Underserved NCORP</td>
<td>7</td>
<td>-</td>
</tr>
<tr>
<td>Oregon Health and Science University</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>UC Davis Comprehensive Cancer Center LAPS</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>USC Norris Comprehensive Cancer Center LAPS</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>University of Kansas Cancer Center - MCA Rural MU NCORP</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>University of Michigan Comprehensive Cancer Center LAPS</td>
<td>10</td>
<td>-</td>
</tr>
<tr>
<td>University of Utah - Huntsman Cancer Institute LAPS</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Wayne State University - Karmanos Cancer Institute LAPS</td>
<td>6</td>
<td>-</td>
</tr>
<tr>
<td>ALLIANCE</td>
<td>23</td>
<td>-</td>
</tr>
<tr>
<td>ECOG-ACRIN</td>
<td>43</td>
<td>-</td>
</tr>
<tr>
<td>NRG</td>
<td>24</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>309</strong></td>
<td><strong>3</strong></td>
</tr>
</tbody>
</table>